Sandra P. D’Angelo

Microsatellite Instability Identifies a Rare but Clinically Relevant Subset of Sarcomas: Insights from the Largest Clinically Sequenced Cohort with Therapeutic Implications

Carla Saoud, Chad Vanderbilt, Jamal Benhamida, Carol D. Morris et autres

us (code pays fourni par la source)

Supplementary Figure S3 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, Martina Bradić et autres

Supplementary Figure S1 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, Martina Bradić et autres

Supplementary Table S3 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, Martina Bradić et autres

Data from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, Martina Bradić et autres

Supplementary Figure S5 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, Martina Bradić et autres

Supplementary Figure S4 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, Martina Bradić et autres

Supplementary Table S1 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, Martina Bradić et autres

Supplementary Table S2 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, Martina Bradić et autres

Supplementary Figure S2 from Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma

Evan Rosenbaum, Fiona Ehrich, Mohammad Yosofvand, Martina Bradić et autres

The ATLAS study: A first-in-human phase 1/2 trial of [Ac-225]RTX-2358 in patients with relapsed or refractory soft tissue sarcoma.

Sandra P. D’Angelo, William D. Tap, Ankit Mangla, Michael S. Nakazawa et autres

us, ca (code pays fourni par la source)

Abstract CT295: Phase I trial of CRD3874-SI, a systemically administered third generation allosteric STING agonist, in patients with advanced solid tumors

Ciara M. Kelly, Reinhard von Roemeling, Monali Banerjee, Viswatej Avutu et autres

us, gb (code pays fourni par la source)